Health & Medicinearticle2026-09-28

Site-dependent treg cell transcriptional reprograming in a metastatic colorectal cancer model holds prognostic significance

Open access0 citations

Abstract

In colorectal cancer (CRC), tumor-infiltrating regulatory T (Treg) cells suppress anti-tumor immunity, promoting immune evasion and tumor progression. Effective therapies require selectively targeting tumor-infiltrating Treg (TI-Treg) cells while preserving systemic Treg cells, necessitating insight into their adaptations within the tumor microenvironment. Here, CRC-organoids were implanted in the liver of Foxp3eGFP mice to investigate location-specific phenotypic differences in TI-Treg cells. In our cohort, tumor tissue exhibited an increased proportion of Treg cells and a decrease proportion of effector CD4+ and CD8+ T cells compared to matched healthy tissue. RNA sequencing of Treg cells isolated from the spleen, primary liver tumor transplant, or metastases identified gene expression profiles previously associated with CRC-related Treg cells in patients. Location-specific differences included elevated expression of WNT-pathway genes in peritoneal TI-Treg cells compared to liver counterparts. Higher expression of genes upregulated in liver TI-Treg cells correlated with poor CRC prognosis. Splenic Treg cells from tumor-bearing mice displayed distinct transcriptional profiles from both their healthy counterparts and TI-Treg cells, suggesting they represent a distinct CD4+ population. Taken together, these findings highlight TI-Treg cells heterogeneity across different tumor sites and the distinct nature of splenic Treg cells in tumor-bearing hosts.

// Source

Open access versionPublisher pageOpenAlexUtrecht University Repository (Utrecht University)Published 2026-09-28

Authors: Sonia Aristin Revilla, André Verheem, Cynthia Lisanne Frederiks, Yongsoo Kim, Theofilos Chalkiadakis, Bastiaan J. Viergever, Balázs Győrffy, Enric Mocholí, Onno Kranenburg, Stefan Preković, Paul James Coffer, CMM Groep Coffer, Cancer, Regenerative Medicine and Stem Cells, Lab Translational Oncology, CTI Eijkelkamp, CMM Groep Prekovich, MS Urologische Oncologie, CMM Sectie Stem Cells, Infection & Immunity